The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical ...
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...
Superior efficacy at 12 weeks was seen with the frontline combination of abemaciclib and endocrine therapy vs standard ...
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
CDK4/6 inhibitors are targeted drugs that can be used for women with a common type of breast cancer: hormone ...
The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early ...
The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) ...
Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Metastatic Renal Cell Carcinoma.
POETIC-A is investigating whether adding the drug abemaciclib alongside hormone therapy can help prevent higher risk early breast cancer from returning. Abemaciclib works by blocking molecules which ...
With 1 in 4 Singaporeans likely to get some form of cancer during their lifetime, getting comprehensive coverage is more ...